Xenon Pharmaceuticals

NASDAQ: XENE

$54.26USD

-0.98 (-1.77%)At close: Apr 27, 20:00 UTC

Open

$54.32

Prev. Close

$54.31

High

$54.32

Low

$54.17

Key Stats

Market Cap

$4.19B

Dividend Yield

–

P/E Ratio

-12.1

EPS

-3.02

Revenue

Avg. Volume

659.3K

TL;DR

emptyResult

Recently from Cashu

Xenon Pharmaceuticals Advances Neurological Drug Development with Promising Phase III Trial Results.

Xenon Pharmaceuticals showcases promising advancements in drug development with Azetukalner, a medication aimed at treating neurological disorders, as evidenced by the strong Phase III clinical trial…

Cashu Markets·7h ago

Xenon Pharmaceuticals Advances Epilepsy Treatment with Successful X-TOLE2 Trial Results

Xenon Pharmaceuticals Pioneers New Frontiers in Epilepsy Treatment with X-TOLE2 Trial Success Xenon Pharmaceuticals Inc. has achieved a significant milestone with its recent Phase 3 clinical trial, X-…

Cashu Markets·2 months ago

Xenon Pharmaceuticals Achieves Positive Phase 3 Trial Results for Innovative Seizure Treatment

Xenon Pharmaceuticals Advances Seizure Treatment in Positive Phase 3 Trial Results Xenon Pharmaceuticals Inc. (NASDAQ:XENE) makes significant strides in developing innovative treatments for epilepsy,…

Cashu Markets·2 months ago

Xenon Pharmaceuticals Monitors Biohaven's Promising Advances in Major Depressive Disorder Treatments

Biohaven’s Innovative Approach to Major Depressive Disorder Shows Promise In a recent development in the mental health treatment landscape, Biohaven Ltd. announces the outcomes of its Phase 2 proof-of…

Cashu Markets·4 months ago